RANBAXY UK LTD. LAUNCHES ESOMEPRAZOLE

Printer-friendly versionPDF version

First approved generic version of the product to be made available in the UK

London, UK and Gurgaon, India, September 5, 2011

Ranbaxy (UK) Ltd. announced that it has successfully launched esomeprazole 20 mg and 40 mg tablets, the first approved generic bio-equivalent version of the product NexiumTM, in the United Kingdom (UK), with annual UK sales of £ 60 Mn (IMS June 2011).

Commenting on the development, Debashis Dasgupta, Regional Director, Ranbaxy Europe, said, “We are committed to bringing high quality, affordable medicines for the benefit of patients and healthcare systems worldwide and in Europe. The introduction of esomeprazole, in the UK, is an important and significant step in this direction.”

The product will be offered through pharmacies, retail and wholesale stores with immediate effect.

Esomeprazole is used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome.

Ranbaxy (UK) Ltd. (RUKL) is the wholly owned subsidiary of Ranbaxy Laboratories Limited in the UK. Established in 1994, RUKL is today one of the major generic companies in this market providing medicines in the cardiovascular, CNS, anti-infective, gastroenterology, anti-viral, anti-inflammatory, oncology and pain relief therapeutic segments.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company’s commitment to increase penetration and improve access to medicines, across the globe.

 Nexium^TMis the registered trademark of Astra Zeneca.

News Source : RANBAXY UK LTD. LAUNCHES ESOMEPRAZOLE